Treatment of high-risk cervical cancer [1] (multiple letters)

New England Journal of Medicine

Volumn 341, Issue 9, 1999, Pages 695-697

  Pearcey, R G ^a   Mohamed, I G ^a   Hanson, J ^a   Piver, M S ^a   Morris, M ^a   Eifel, P J ^a   Rose, P G ^a   Bundy, B N ^a  

^a CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; HYDROXYUREA;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LETTER; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; RADIATION DOSAGE; UTERINE CERVICAL NEOPLASMS;

EID: 0033606919     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199908263410913     Document Type: Letter

References (0)